The UN Intergovernmental Panel on Climate Change (IPCC) has released a new report providing multiple options for how the world can survive and adapt to climate change.
"The climate time bomb is ticking," said U.N. Secretary-General António Guterres in a press release. "But today's IPCC report is a how-to guide to defuse the climate time bomb. It is a survival guide for humanity."
The IPCC's Synthesis Report is the most comprehensive document from the agency since the 2015 Paris Agreement and is intended to serve as a set of guidelines for governments around the world to keep warming within 1.5°C.
The agency stressed that carbon emissions have only increased since the agency established that temperature limit in 2018. Global temperatures are currently 1.1°C above pre-industrial levels, which the agency said has caused more frequent and intense extreme weather events around the world.
"Mainstreaming effective and equitable climate action will not only reduce losses and damages for nature and people, it will also provide wider benefits," said IPCC Chair Hoesung Lee. "This [report] underscores the urgency of taking more ambitious action and shows that, if we act now, we can still secure a liveable sustainable future for all."
The UN panel is calling for "climate resilient development" to reduce emissions and increased investment in developing clean energy sources and new transportation options that emphasize walking, cycling, and public transport.
"Transformational changes are more likely to succeed where there is trust, where everyone works together to prioritize risk reduction, and where benefits and burdens are shared equitably," Lee said. "We live in a diverse world in which everyone has different responsibilities and different opportunities to bring about change. Some can do a lot while others will need support to help them manage the change."
An FDA panel has recommended the low-dose Pfizer vaccine for kids ages five to 11. The recommendation now cues up the FDA to authorize the vaccine. Next week, the CDC will consider its own authorization. Once signed off by the CDC, the Pfizer vaccine can be administered in children immediately. Dr. Christina Johns, Senior Medical Advisor at PM Pediatrics, joined Cheddar's Search for a Cure.
Dr. Vivek Cherin, Internal Medicine Physician at Amita Health, joined Cheddar's Search for a Cure to break down what we need to know about eligibility and availability of COVID-19 vaccine boosters.
World leaders will converge this weekend at the 2021 G20 Summit in Rome and the UN COP26 conference in Glasgow with the climate crisis on the agenda. Lord Adair Turner, chair of the Energy Transitions Commission, joined Cheddar to discuss what people can expect to come out of the climate-focused conferences. Turner also noted that one of the biggest hurdles for the attending nations will be coming to a uniform decision on expanding on the Paris Climate Accord goals that have become insufficient to prevent global warming by 1.5 degrees celsius.
Nicole Lambert, President at Myriad Genetics joins ChedHER to discuss how to expand access to genetic testing for all women, and how her experience as a 'pre-vivor' motivates her role in the industry.
Carlo and Baker cover Facebook's big rebrand, the latest on Biden's economic agenda and more. Plus, ranking the best Halloween candy and the worst couple's costumes.
Proptech startup Juno recently raised $20 million in a Series A funding round. The company says the funds will be used to further its mission of building sustainable and affordable apartment buildings across the United States. Juno Co-Founder and CEO Jonathan Sherr joined Cheddar News' Closing Bell to discuss.
Stacey Stevens, President of iCAD, joins 'Cheddar Innovates' to discuss how 'Profound A.I. Risk' works as a short-term breast cancer risk estimation for women.
On this episode of 'Cheddar Innovates': President of iCAD breaks down how its technology is being used as a short-term breast cancer risk estimation for women; A look at Curiosity Stream's 'The Science of Thrills.'
Pharmaceutical company Merck has announced that it will share the formula of its COVID-19 pill with poor countries free of charge. The company still intends to charge wealthier nations leaving the end cost at more than $700 per five-day treatment course.
Dems race for a deal on President Biden's economic agenda ahead of his big foreign trip. What to make of the latest threat assessment in Afghanistan. Plus, the meme cryptocurrency of the moment that's now worth more than many Fortune 500 companies.
